A Combined Metabonomics and Proteomics Approach to Biomarker Discovery for Schizophrenia Using Accurate Mass LC-MS
In this study we employed a label free quantitative mass
spectrometry-based approach to analyze the metabolic and protein
profiles in cerebrospinal fluid (CSF) samples from first-onset, drug
naïve schizophrenia patients and demographically-matched healthy
controls. As collection of CSF is a highly invasive procedure matched
serum samples, which can be collected more routinely, were also
analysed for the presence of potential biomarkers.